REG - PureTech Health PLC - PDMR Notification RSU Vesting

Puretech HealthAnnouncement

27/06/2024 17:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240627:nRSa2119Ua&default-theme=true

RNS Number : 2119U  PureTech Health PLC  27 June 2024

27 June 2024

PureTech Health plc

 

PDMR Notifications

 

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a
clinical-stage biotherapeutics company dedicated to giving life to new classes
of medicine to change the lives of patients with devastating diseases,
announces that awards of restricted share units ("RSUs") granted by PureTech
on 8 June 2023 to certain non-executive directors ("PDMRs") pursuant to its
Performance Share Plan ("PSP") vested in full on 12 June 2024 the day
immediately prior to the Company's Annual General Meeting of Stockholders.
Each PDMR received vested ordinary shares on 26 June 2024.

The Company's total issued ordinary share capital is 257,927,489 shares after
the share issuance to the PDMRs, 18,523,299 shares of which are held in
treasury by the Company.

PDMR Notification

 

The information contained in the below notification is disclosed in accordance
with Article 19 of the EU Market Abuse Regulation.

 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a)  Name                                                         Raju Kucherlapati

                                                                  John LaMattina

                                                                  Robert Langer

                                                                  Kiran Mazumdar-Shaw

                                                                  Sharon Barber-Lui

 2   Reason for the notification
 a)  Position/status                                              Non-Executive Directors
 b)  Initial notification/Amendment                               Initial Notification
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         PureTech Health plc
 b)  LEI                                                          213800LVPDNO2Z9T9I39
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument  Ordinary Shares of PureTech Health plc

                                                                  ISIN GB00BY2Z0H74
 b)  Nature of the transaction                                    Issuance of ordinary shares in settlement of certain vested RSUs under the
                                                                  PureTech Health Performance Share Plan.
 c)  Price(s) and volume(s)                                       Recipient            Price     Amount
                                                                  Raju Kucherlapati    0.01 GBP  17,122 ordinary shares
                                                                  John LaMattina       0.01 GBP  17,122 ordinary shares
                                                                  Robert Langer        0.01 GBP  17,122 ordinary shares
                                                                  Kiran Mazumdar-Shaw  0.01 GBP  17,122 ordinary shares
                                                                  Sharon Barber-Lui    0.01 GBP  17,122 ordinary shares
 d)  Aggregated information                                       Price     Aggregate Volume

- Aggregated volume                                         0.01 GBP  85,610 ordinary shares

- Price
 e)  Date of the transaction                                      26 June 2024
 f)  Place of the transaction                                     London Stock Exchange (XLON)

b)

Nature of the transaction

Issuance of ordinary shares in settlement of certain vested RSUs under the
PureTech Health Performance Share Plan.

c)

Price(s) and volume(s)

 Recipient            Price     Amount
 Raju Kucherlapati    0.01 GBP  17,122 ordinary shares
 John LaMattina       0.01 GBP  17,122 ordinary shares
 Robert Langer        0.01 GBP  17,122 ordinary shares
 Kiran Mazumdar-Shaw  0.01 GBP  17,122 ordinary shares
 Sharon Barber-Lui    0.01 GBP  17,122 ordinary shares

d)

Aggregated information

 -  Aggregated volume

 -  Price

 Price     Aggregate Volume
 0.01 GBP  85,610 ordinary shares

e)

Date of the transaction

26 June 2024

f)

Place of the transaction

London Stock Exchange (XLON)

 

About PureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to giving life
to new classes of medicine to change the lives of patients with devastating
diseases. The Company has created a broad and deep pipeline through its
experienced research and development team and its extensive network of
scientists, clinicians and industry leaders that is being advanced both
internally and through its Founded Entities. PureTech's R&D engine has
resulted in the development of 29 therapeutics and therapeutic candidates,
including two that have received both U.S. FDA clearance and European
marketing authorization and a third (KarXT) that has been filed for FDA
approval. A number of these programs are being advanced by PureTech or its
Founded Entities in various indications and stages of clinical development,
including registration enabling studies. All of the underlying programs and
platforms that resulted in this pipeline of therapeutic candidates were
initially identified or discovered and then advanced by the PureTech team
through key validation points.

For more information, visit www.puretechhealth.com
(http://www.puretechhealth.com/)  or connect with us on X (formerly Twitter)
@puretechh.

 

Contact:

PureTech

Investor Relations

IR@puretechhealth.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHPPUQAQUPCGWM